Cargando…

Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma

Von Hippel-Lindau (VHL) syndrome is a rare inherited cancer disease where the lack of VHL protein triggers the development of multisystemic tumors such us retinal hemangioblastomas (HBs), CNS-HBs, and clear cell renal cell carcinoma (ccRCC). Since standard therapies in VHL have shown limited respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albiñana, Virginia, Recio-Poveda, Lucía, González-Peramato, Pilar, Martinez-Piñeiro, Luis, Botella, Luisa María, Cuesta, Angel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835934/ https://www.ncbi.nlm.nih.gov/pubmed/35163250 http://dx.doi.org/10.3390/ijms23031325

Ejemplares similares

Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel–Lindau Disease
por: Albiñana, Virginia, et al.
Publicado: (2020)

The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases
por: Cuesta, Angel M., et al.
Publicado: (2022)

Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
por: Albiñana, Virginia, et al.
Publicado: (2022)

CLN5 in heterozygosis may protect against the development of tumors in a VHL patient
por: de Rojas-P, Isabel, et al.
Publicado: (2020)

Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding
por: Albiñana, Virginia, et al.
Publicado: (2020)

Research on potential biomarkers in hereditary hemorrhagic telangiectasia
por: Botella, Luisa-María, et al.
Publicado: (2015)

The Endothelial Landscape and Its Role in Von Hippel–Lindau Disease
por: de Rojas-P, Isabel, et al.
Publicado: (2021)

Topically Applied Etamsylate: A New Orphan Drug for HHT-Derived Epistaxis (Antiangiogenesis through FGF Pathway Inhibition)
por: Albiñana, Virginia, et al.
Publicado: (2019)

The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease
por: Cuesta, A. M., et al.
Publicado: (2019)

A Novel Splicing Mutation in the ACVRL1/ALK1 Gene as a Cause of HHT2
por: Errasti Díaz, Suriel, et al.
Publicado: (2022)

SARS-CoV-2 Infection in Hereditary Hemorrhagic Telangiectasia Patients Suggests Less Clinical Impact Than in the General Population
por: Marcos, Sol, et al.
Publicado: (2021)

Proteomics Characterization of Clear Cell Renal Cell Carcinoma
por: Miranda-Poma, Jesús, et al.
Publicado: (2023)

Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial
por: González-Rodríguez, Beatriz, et al.
Publicado: (2019)

Mutation affecting the proximal promoter of Endoglin as the origin of hereditary hemorrhagic telangiectasia type 1
por: Albiñana, Virginia, et al.
Publicado: (2017)

Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease
por: Albiñana, Virginia, et al.
Publicado: (2017)

Prognostic role of the beta-2 adrenergic receptor in clear cell renal cell carcinoma
por: Ha, Mihyang, et al.
Publicado: (2019)

Copy number variations in endoglin locus: mapping of large deletions in Spanish families with hereditary hemorrhagic telangiectasia type 1
por: Fontalba, Ana, et al.
Publicado: (2013)

Beta-Adrenergic Blockade in Critical Illness
por: Bruning, Rebecca, et al.
Publicado: (2021)

Beta adrenergic blockade reduces utilitarian judgement
por: Sylvia, Terbeck, et al.
Publicado: (2013)

Differential Expression of Circulating Plasma miRNA-370 and miRNA-10a from Patients with Hereditary Hemorrhagic Telangiectasia
por: Ruiz-Llorente, Lidia, et al.
Publicado: (2020)

Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
por: Yoshida, Takashi, et al.
Publicado: (2021)

Adrenergic regulation of immune cell function and inflammation
por: Sharma, Drashya, et al.
Publicado: (2020)

Opioid Facilitation of β-Adrenergic Blockade: A New Pharmacological Condition?
por: Vamecq, Joseph, et al.
Publicado: (2015)

Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis
por: Suzuki, Takeshi, et al.
Publicado: (2017)

Targeting β(3)-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade
por: Cannavo, Alessandro, et al.
Publicado: (2017)

CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
por: Zhou, Quan, et al.
Publicado: (2020)

Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds
por: Marcos, Sol, et al.
Publicado: (2021)

Adrenergic receptor blockade attenuates placental ischemia‐induced hypertension
por: Spradley, Frank T., et al.
Publicado: (2018)

α (1)-Adrenergic Receptor Blockade by Prazosin Synergistically Stabilizes Rat Peritoneal Mast Cells
por: Abe, Nozomu, et al.
Publicado: (2020)

A novel inflammation-associated prognostic signature for clear cell renal cell carcinoma
por: Liu, Gangcheng, et al.
Publicado: (2022)

β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure
por: Machackova, Jarmila, et al.
Publicado: (2011)

β-Adrenergic blockade in patients with dementia and hip fracture is associated with decreased postoperative mortality
por: Ioannidis, Ioannis, et al.
Publicado: (2021)

SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients
por: Li, Pengju, et al.
Publicado: (2020)

Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma
por: Yin, Xiaomao, et al.
Publicado: (2021)

MET Inhibition in Clear Cell Renal Cell Carcinoma
por: Xie, Zuoquan, et al.
Publicado: (2016)

GRK2 blockade with βARKct is essential for cardiac β(2)-adrenergic receptor signaling towards increased contractility
por: Salazar, Norma C, et al.
Publicado: (2013)

Heart rate control with adrenergic blockade: Clinical outcomes in cardiovascular medicine
por: Feldman, David, et al.
Publicado: (2010)

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
por: Embaby, Alaa, et al.
Publicado: (2022)

Expression of Adrenergic and Cholinergic Receptors in Murine Renal Intercalated Cells
por: JUN, Jin-Gon, et al.
Publicado: (2014)

Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma
por: Chang, Y, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9ha1nvnnfl4i748cu5bql4vpau